Clifton E Barry

Section Chief

National Institute of Allergy and Infectious Diseases

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Clifton E Barry is the Section Chief at the National Institute of Allergy and Infectious Diseases in the United States. His research primarily focuses on tuberculosis therapy, including strategies for shortening its treatment and addressing multidrug-resistant strains. His recent publications explore various aspects of Mycobacterium tuberculosis, including novel compounds and mathematical modeling for better understanding of drug transport within granulomas.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (3)

Christoph Lange

University of Lübeck

GERMANY

View details

Meenal Datta

University of Notre Dame

UNITED STATES

View details

Jennifer Herrmann

Helmholtz Institute for Pharmaceutical Research Saarland

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Clifton E Barry

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Strategies for shortening tuberculosis therapy

Mathematical model of oxygen, nutrient, and drug transport in tuberculosis granulomas

Environmental fungi target thiol homeostasis to compete with Mycobacterium tuberculosis

A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial

The Antitubercular Activities of Natural Products with Fused-Nitrogen-Containing Heterocycles

The Myxobacterial Antibiotic Myxovalargin: Biosynthesis, Structural Revision, Total Synthesis, and Molecular Characterization of Ribosomal Inhibition

Synthesis and Structure-Activity Relationships of a New Class of Oxadiazoles Targeting DprE1 as Antitubercular Agents.

Chemical approaches to unraveling the biology of mycobacteria.

A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum.

Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel

Collaborators (3)

Christoph Lange

Meenal Datta

Jennifer Herrmann

Make your next move.